Gaboxadol meets Phase II endpoints

Merck (MRK) and H.Lundbeck (CSE:LUN) said gaboxadol met the endpoints of total time awake, total sleep time, latency to persistent sleep and slow wave sleep in a Phase II trial to treat primary insomn...